{
  "run_id": "kag_qa_pet_20260210T183650Z",
  "graph_dir": "experiments/KAG/results/sprint4_pet_20260210T152550Z",
  "paper": "pet",
  "model": "anthropic/claude-sonnet-4-5-20250929",
  "questions_answered": 6,
  "total_cost": 0.458511,
  "results": [
    {
      "question_id": "pet_structural_01",
      "question": "List all sections and subsections in this paper.",
      "type": "structural",
      "answer": "Sections and subsections in the paper:\n\n- ARTICLE INFO\n- A B S T R A C T\n- 1. Introduction\n- 2. Experimental\n  - 2.1. Nivolumab conjugation with DFO\n  - 2.2. Radiolabeling and quality control of  \\( ^{89} \\) Zr-nivolumab\n  - 2.3. Animal preparation\n  - 2.4. Magnetic resonance imaging\n  - 2.5. Positron emission tomography imaging and image analysis\n- 3. Results and discussion\n  - 3.1. Conjugation and characterization of nivolumab-DFO\n  - 3.2. Radiolabeling and quality control of  \\( ^{89} \\) Zr-nivolumab\n  - 3.3. In vivo PET imaging in normal healthy cynomolgus monkeys\n- 4. Conclusion\n- Conflict of interest statement\n- Acknowledgements\n- Supplementary data\n- References",
      "iterations": 4,
      "tools_used": [
        "g_search",
        "g_section_content"
      ],
      "tool_counts": {
        "g_search": 1,
        "g_section_content": 24
      },
      "cost": 0.065079,
      "lm_usage": {
        "total_calls": 4,
        "prompt_tokens": 12548,
        "completion_tokens": 1829,
        "total_tokens": 14377,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.065079
      }
    },
    {
      "question_id": "pet_content_01",
      "question": "What is the radiochemical yield and purity of 89Zr-nivolumab reported in this study?",
      "type": "content",
      "answer": "The radiochemical yield and purity of 89Zr-nivolumab reported in this study are:\n\n**Radiochemical Yield**: 53 \u00b1 8% (non-decay-corrected)\n\n**Radiochemical Purity**: \n- 90% for tracer only\n- 87% for carrier-added conditions (both 1 mg/kg and 3 mg/kg)\n\nNote: The radiochemical purity values represent single peak with impurity of high molecular weight species (HMWs).",
      "iterations": 4,
      "tools_used": [
        "g_search",
        "g_node_detail"
      ],
      "tool_counts": {
        "g_search": 1,
        "g_node_detail": 4
      },
      "cost": 0.060477,
      "lm_usage": {
        "total_calls": 4,
        "prompt_tokens": 12369,
        "completion_tokens": 1558,
        "total_tokens": 13927,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.060477
      }
    },
    {
      "question_id": "pet_cross_ref_01",
      "question": "What data does Table 1 contain? Which paragraphs reference it?",
      "type": "cross_ref",
      "answer": "Table 1 contains \"Injected Doses of \u2078\u2079Zr-Nivolumab for Tracer only and Carrier-Added Studies in NHPs.\"\n\nThe table presents data for three experimental conditions:\n1. Tracer only\n2. Carrier-Added 1 mg/kg\n3. Carrier-Added 3 mg/kg\n\nFor each condition, the table provides:\n- \u2078\u2079Zr-nivolumab (RCY) - radiochemical yield values (225 MBq, 341 MBq, and 252 MBq respectively)\n- Specific activity (EOS) - end of synthesis values (252 MBq/mg, 402 MBq/mg, and 402 MBq/mg)\n- Radiochemical Purity (90%, 87%, and 87%)\n- Body weight NHP (non-human primate)\n- Injected dose\n- Injected activity\n\nThe table is referenced by one paragraph:\n- Paragraph ex:b_p005_0010 (page 5), which states: \"specific activity was calculated to be 352 \u00b1 87 MBq/mg, see Table 1 for individual reaction data.\"\n",
      "iterations": 4,
      "tools_used": [
        "g_search",
        "g_node_detail",
        "g_node_refs"
      ],
      "tool_counts": {
        "g_search": 2,
        "g_node_detail": 3,
        "g_node_refs": 1
      },
      "cost": 0.068685,
      "lm_usage": {
        "total_calls": 4,
        "prompt_tokens": 13745,
        "completion_tokens": 1830,
        "total_tokens": 15575,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.068685
      }
    },
    {
      "question_id": "pet_citation_01",
      "question": "How many references does this paper cite? List the first 5 by number and title.",
      "type": "citation",
      "answer": "This paper cites 37 references.\n\nThe first 5 references by number and title are:\n\n1. Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015;36:198\u2013216.\n\n2. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9:269\u2013277.\n\n3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278\u2013287.\n\n4. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239\u2013245.\n\n5. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580\u20139587.",
      "iterations": 10,
      "tools_used": [
        "g_search",
        "g_section_content",
        "g_node_detail",
        "g_node_refs"
      ],
      "tool_counts": {
        "g_search": 6,
        "g_section_content": 22,
        "g_node_detail": 16,
        "g_node_refs": 1
      },
      "cost": 0.18321600000000002,
      "lm_usage": {
        "total_calls": 10,
        "prompt_tokens": 40487,
        "completion_tokens": 4117,
        "total_tokens": 44604,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.18321600000000002
      }
    },
    {
      "question_id": "pet_synthesis_01",
      "question": "What is the main conclusion about 89Zr-nivolumab biodistribution in the spleen?",
      "type": "synthesis",
      "answer": "The main conclusion about 89Zr-nivolumab biodistribution in the spleen is that it shows specific biodistribution to the spleen, and this uptake can be blocked by co-administration of excess unlabeled nivolumab. Specifically, carrier-added studies with 1 and 3 mg/kg nivolumab demonstrated that spleen uptake was reduced by an average of 82.5 \u00b1 4.6% (range: -75.2% to -87.0%) compared to tracer-only studies. This blockable uptake indicates that the spleen biodistribution is specific and receptor-mediated (PD-1 binding) rather than non-specific accumulation.",
      "iterations": 3,
      "tools_used": [
        "g_search",
        "g_node_detail"
      ],
      "tool_counts": {
        "g_search": 1,
        "g_node_detail": 3
      },
      "cost": 0.042147,
      "lm_usage": {
        "total_calls": 3,
        "prompt_tokens": 8089,
        "completion_tokens": 1192,
        "total_tokens": 9281,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.042147
      }
    },
    {
      "question_id": "pet_content_02",
      "question": "What were the K_D values for nivolumab and nivolumab-DFO binding to hPD-1?",
      "type": "content",
      "answer": "The K_D values for nivolumab and nivolumab-DFO binding to hPD-1 are:\n- Nivolumab: 3.10 nM\n- Nivolumab-DFO: 3.75 nM",
      "iterations": 3,
      "tools_used": [
        "g_search",
        "g_node_detail"
      ],
      "tool_counts": {
        "g_search": 1,
        "g_node_detail": 1
      },
      "cost": 0.038907,
      "lm_usage": {
        "total_calls": 3,
        "prompt_tokens": 8234,
        "completion_tokens": 947,
        "total_tokens": 9181,
        "cache_read_tokens": 0,
        "cache_creation_tokens": 0,
        "total_cost": 0.038907
      }
    }
  ]
}